Literature DB >> 2051498

Alprazolam and diazepam: addiction potential.

S Juergens1.   

Abstract

Alprazolam and diazepam, the two most prescribed benzodiazepine anxiolytics in the United States, have potential for addictive use. The Drug Abuse Warning Network (DAWN) indicates they are the most mentioned benzodiazepines, and the National Household Survey indicates significant abuse of tranquilizers. Both drugs are rapidly absorbed and enter the brain tissue rapidly, leading to reinforcement. Alprazolam has a shorter half-life, which may lead to more withdrawal symptoms than diazepam. In experimental conditions, they are among the most reinforcing benzodiazepines. Each causes a withdrawal syndrome, but alprazolam withdrawal may be more severe and may occur after a shorter period of use. Adverse effects from their use are said to be rare, yet subtle negative consequences may be seen with some regularity. Alprazolam deserves special caution because of its relative newness, great popularity, reinforcing capabilities, relatively severe withdrawal syndrome, and reports of addiction and negative consequences of use.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2051498     DOI: 10.1016/0740-5472(91)90026-7

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  9 in total

Review 1.  A Review of Alprazolam Use, Misuse, and Withdrawal.

Authors:  Nassima Ait-Daoud; Allan Scott Hamby; Sana Sharma; Derek Blevins
Journal:  J Addict Med       Date:  2018 Jan/Feb       Impact factor: 3.702

2.  An Updated Analysis of Psychotropic Medicine Utilisation in Older People in New Zealand from 2005 to 2019.

Authors:  Prasad S Nishtala; Te-Yuan Chyou
Journal:  Drugs Aging       Date:  2022-07-13       Impact factor: 4.271

3.  Assessing methylphenidate preference in ADHD patients using a choice procedure.

Authors:  Emily MacDonald Fredericks; Scott H Kollins
Journal:  Psychopharmacology (Berl)       Date:  2004-10       Impact factor: 4.530

4.  Preferences for ethanol and diazepam in anxious individuals: an evaluation of the self-medication hypothesis.

Authors:  M A Chutuape; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  1995-09       Impact factor: 4.530

Review 5.  Pharmacological treatment of vertigo.

Authors:  Timothy C Hain; Mohammed Uddin
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

6.  Case report on the administration of an eighty milligram diazepam injection without respiratory depression.

Authors:  Morteza Abdar Esfahani; Arash Beiki; Sedigheh Asgarian
Journal:  Adv Biomed Res       Date:  2014-12-12

Review 7.  Management of the psychological comorbidities of dermatological conditions: practitioners' guidelines.

Authors:  Cody J Connor
Journal:  Clin Cosmet Investig Dermatol       Date:  2017-04-20

8.  Alprazolam-related deaths in Scotland, 2004-2020.

Authors:  John Martin Corkery; Amira Guirguis; Stefania Chiappini; Giovanni Martinotti; Fabrizio Schifano
Journal:  J Psychopharmacol       Date:  2022-08-01       Impact factor: 4.562

9.  Pharmacological Targeting the REV-ERBs in Sleep/Wake Regulation.

Authors:  Ariadna Amador; Salvador Huitron-Resendiz; Amanda J Roberts; Theodore M Kamenecka; Laura A Solt; Thomas P Burris
Journal:  PLoS One       Date:  2016-09-07       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.